Laekna makes third deal with Novartis, taking global rights to PD-L1 candidate

Shanghai-based biotech Laekna Therapeutics Shanghai Co., Ltd, signed with Novartis AG (NYSE.NVS) for exclusive global rights to the Swiss firm’s anti-programmed death-ligand 1 (PD-L1) drug candidate FAZ053. No financial specifics were disclosed.

Originated by Novartis, FAZ053 has previously completed Phase I clinical trials demonstrating safety and efficacy in patients with a range of solid tumors. The checkpoint inhibitor binds to PD-L1 on tumor cells, preventing their binding to PD-1 receptor on T-cells and thereby inhibiting tumor immune evasion. Laekna states that it aims to put the drug into combination therapies with chemotherapies or targeted small molecule drugs, and has already planned several strategies focused on cancers that are resistant to checkpoint inhibitor treatments.

The deal is the third time that Laekna has picked up global rights to oncology candidates from Novartis. In July 2017, Novartis handed over the CYP17 inhibitor CFG920, an oral androgen inhibitor designed to treat prostate cancer; and Laekna picked up two former GlaxoSmithKline oncology drugs, the oral pan-Akt kinase inhibitors afuresertib (ASB183) and uprosertib (UPB795) in an August 2018 deal previously reported by GBI. That deal led to Novartis taking an undisclosed equity stake in Laekna, which was established in 2016 and secured USD 18.5 million in Series A backing, led by OrbiMed Asia, in 2018.


Related news
China-based biotech Laekna Inc., announced an agreement with Swiss firm Novartis Pharma AG that grants exclusive global development and commercialization rights to two clinical-stage candidates.
Recent news
The National Medical Products Administration (NMPA) last week revealed that Celgene’s Abraxane (paclitaxel, albumin bound) would lose its import clearance after agency inspectors uncovered manufacturing issues at the Fresenius Kabi plant responsible for manufacturing the drug. The news impacts Chinese biotech BeiGene Inc., which generated around USD 100 million with Abraxane in China as the drug's marketing agent under license from Celgene.
  • 1585666816337
  • China
Pfizer subsidiary Wyeth this week obtained a marketing approval from Brazil's National Health Surveillance Agency (ANVISA) for its iron replacement therapy Monofer (ferric derisomaltose), as GBI analysis shows.
Hugo Sigman, founder of of Argentina-based group Insud Pharma, last week commented on Argentina’s biopharmaceutical industry as the COVID-19 pandemic puts the health sector to test.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) released its Q4 2019 financial report.
According to GBI analysis, Mexico’s Federal Commission for the Protection against Health Risks (COFEPRIS) has published recent market approvals for Swiss major Novartis subsidiary Sandoz’s Arasamila (rituximab), Japan-based Daiichi Sankyo’s factor Xa (FXa) inhibitor Lixiana (edoxaban), and compatriot Takeda branch Baxalta’s antihemophilic Adynovate (rurioctocog alfa pegol).
GoBroad Healthcare Group broke ground on construction of a research hospital in Beijing’s Future Science Park this week.
Analytics Snapshot

Analytics Snapshot